5.58

6.08% 0.32

After Hours: 5.57 -0.010 -0.18%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $5.58, with a volume of 831.43K. It is up +6.08% in the last 24 hours and up +1.09% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$5.26

Open:

$5.17

24h Volume:

831.43K

Relative Volume:

0.80

Market Cap:

$822.89M

Revenue:

$170.28M

Net Income/Loss:

$-225.25M

P/E Ratio:

-4.1955

EPS:

-1.33

Net Cash Flow:

$-167.02M

1W Performance:

+18.47%

1M Performance:

+1.09%

6M Performance:

+85.38%

1Y Performance:

+12.27%

1-Day Range:

$5.09

$5.59

1-Week Range:

$4.65

$5.59

52-Week Range:

$2.28

$5.795

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

709

Twitter

@adaptivebiotech

Next Earnings Date

2024-11-07

Latest SEC Filings

ADPT's Discussions on Twitter

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

09:18 AM

Sumitomo Mitsui Trust Group's Strategic Acquisition in Adaptive Biotechnologies - GuruFocus.com

09:18 AM

01:54 AM

Vanguard Group Inc's Strategic Acquisition in Adaptive Biotechno - GuruFocus.com

01:54 AM

Nov 01, 2024

November 2024's Top US Penny Stocks With Growth Potential - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

ADPT (Adaptive Biotechnologies) Cyclically Adjusted Book pe - GuruFocus.com

Oct 31, 2024

Adaptive Biotechnologies (ADPT) Scheduled to Post Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 30, 2024

Cancer Immunotherapy Global Market 2024 To Reach $175.39Billion By 2028 At Rate Of 12.1% - EIN News

Oct 30, 2024

Cancer Immunotherapy Global Market 2024 To Reach $175.39 Billion By 2028 At Rate Of 12.1% - EIN News

Oct 30, 2024

ADPT (Adaptive Biotechnologies) PE Ratio : At Loss (As of Oct. 30, 2024) - GuruFocus.com

Oct 30, 2024

Oct 16, 2024

Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives $7.00 Consensus Price Target from Analysts - MarketBeat

Oct 16, 2024

Oct 15, 2024

Perhaps timely catching Adaptive Biotechnologies Corp (ADPT) would be a good idea - SETE News

Oct 15, 2024

Oct 14, 2024